<DOC>
	<DOC>NCT00932737</DOC>
	<brief_summary>The primary objective of this pilot study is to assess effects of Hyoscine Butylbromide (HBB) 20 mg in comparison to placebo, when used as needed, as measured by the subject's assessment of intensity of abdominal pain associated with cramping (APC) in the treatment of two episodes.</brief_summary>
	<brief_title>(Hyoscine Butylbromide) for Abdominal Pain Associated With Cramping on Demand Basis</brief_title>
	<detailed_description />
	<mesh_term>Abdominal Pain</mesh_term>
	<mesh_term>Scopolamine Hydrobromide</mesh_term>
	<mesh_term>Butylscopolammonium Bromide</mesh_term>
	<criteria>History of recurrent abdominal pain with cramping (APC) for at least three months. Recorded at least two episodes of APC of at least "moderate" intensity (i.e., 5 or above on a 010 point scale) lasting one hour in the eDiary during the runin period. Experiencing daily episode of APC during Runin period Active gastrointestinal disease during the past 12 months including malignancy, inflammatory bowel disease, celiac disease or complete or partial bowel obstruction and who have undergone major gastrointestinal surgery with the past 12 months (patients with history of appendectomy, cholecystectomy, bilateral tubal ligation and csection within past 12 months are allowed in the study).</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>